standard-title Studi Clinici

Studi Clinici

Titolo Fase Stato Sede patologia Strutture coinvolte Dettaglio

ANGIOSARCOMA MAMMARIO: CARATTERISTICHE CLINICOPATOLOGICHE E POTENZIALE IMPATTO PROGNOSTICO DEI MARKERS IMMUNOTERAPICI.

NA

in corso

Angiosarcoma mammario

SC Anatomia Patologica e Citopatologia -

A PHASE 1B/2, MULTICENTER, OPEN-LABEL PLATFORM STUDY OF SELECT IMMUNOTHERAPY COMBINATIONS IN ADULT PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH HIGH PD-L1 EXPRESSION

I/II

in corso

Cancro del polmone non a piccole cellule

- SC Sperimentazioni Cliniche

TROPION-Breast05 A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

III

in corso

CARCINOMA MAMMARIO

- SC Oncologia Clinica Sperimentale di Senologia

AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 2 STUDY OF THE ATR INHIBITOR TUVUSERTIB IN COMBINATION WITH THE PARP INHIBITOR NIRAPARIB OR THE ATM INHIBITOR LARTESERTIB IN PARTICIPANTS WITH BRCA MUTANT AND/OR OMOLOGOUS RECOMBINATION DEFICIENCY HRD)‑POSITIVE EPITHELIAL OVARIAN CANCER THAT PROGRESSED ON PRIOR PARP INHIBITOR THERAPY

II

in corso

CANCRO OVARICO

- SC Oncologia Clinica Sperimentale Uro - Ginecologica

STUDIO DI REAL-EVIDENCE SU PAZIENTI AFFETTI DA CARCINOMA DEL COLON-RETTO METASTATICO (MCRC) CON MUTAZIONE BRAFV600E IN ITALIA: UNO STUDIO PROSPETTICO NON INTERVENTISTICO

NA

in corso

Cancro del colon-retto

- SC Oncologia Clinica Sperimentale Addominale